基于杂交捕获的新一代测序对肺癌治疗决策变化的临床影响
该回顾性研究纳入2011年11月至2015年10月接受基于杂交捕获(HC)的新一代测序(NGS)的101例晚期肺癌患者,HC-NGS在50%患者中识别出临床可操作的基因组改变,42.6%的患者治疗策略发生改变,这些患者总体缓解率为65%。
要点
- HC-NGS在50%的晚期肺癌患者中识别出临床可操作的基因组改变。
- 42.6%的患者因HC-NGS结果改变治疗策略,其总体缓解率为65%。
- HC-NGS在15例既往标准检测阴性的患者中识别出EGFR/ALK异常。
核心结论
- HC-NGS影响了近半数肺腺癌患者的治疗决策,并与65%的总体缓解率相关,可能转化为生存获益。
研究设计与样本
- 回顾性研究,纳入2011年11月至2015年10月接受HC-NGS的晚期肺癌患者101例,中位年龄63岁,女性53%,从不吸烟者45%,腺癌85%。
主要发现
- HC-NGS在50%的患者中识别出临床可操作的基因组改变,最常见为EGFR(18%)、RET(9%)、ALK(8%)、MET(6%)和ERBB2(5%)。
- HC-NGS在15例既往标准检测阴性的患者中识别出EGFR/ALK异常。
- 43例(42.6%)患者的治疗策略发生改变,这些患者的总体缓解率为65%(完全缓解14.7%,部分缓解50%),中位生存未达到。
- 33例患者接受免疫治疗,多数无可用驱动基因,疾病控制率为32%,并与肿瘤突变负荷相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Targeted therapy significantly prolongs survival in lung adenocarcinoma. Current diagnostic guidelines include only EGFR and anaplastic lymphoma receptor tyrosine kinase gene (ALK) testing. Next-generation sequencing (NGS) reveals more actionable genomic alterations than do standard diagnostic methods. Data on the influence of hybrid capture (HC)-based NGS on treatment are limited, and we investigated its impact on treatment decisions and clinical outcomes. METHODS: This retrospective study included patients with advanced lung cancer on whom HC-based NGS was performed between November 2011 and October 2015. Demographic and clinicopathologic characteristics, treatments, and outcome data were collected. RESULTS: A total of 101 patients were included (median age 63 years [53% females, 45% never-smokers, and 85% with adenocarcinoma]). HC-based NGS was performed upfront and after EGFR/ALK testing yielded negative or inconclusive results in 15% and 85% of patients, respectively. In 51.5% of patients, HC-based NGS was performed before first-line therapy, and in 48.5%, it was performed after treatment failure. HC-based NGS identified clinically actionable genomic alterations in 50% of patients, most frequently in EGFR (18%), Ret proto-oncogene (RET) (9%), ALK (8%), Mesenchymal-epithelial transition factor (MET) receptor tyrosine kinase gene (6%), and erb-b2 receptor tyrosine kinase 2 gene (ERBB2) (5%). In 15 patients, it identified EGFR/ALK aberrations after negative results of prior standard testing. Treatment strategy was changed for 43 patients (42.6%). The overall response rate in these patients was 65% (complete response 14.7%, partial response 50%). Median survival was not reached. Immunotherapy was administered in 33 patients, mostly without an actionable driver, with a presenting disease control rate of 32%, and with an association with tumor mutation burden. CONCLUSIONS: HC-based NGS influenced treatment decisions in close to half of the patients with lung adenocarcinoma and was associated with an overall response rate of 65%, which may translate into a survival benefit.
引用
- Rozenblum AB, Ilouze M, Dudnik E, et al. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer. J Thorac Oncol. 2016. PMID: 27865871. doi:10.1016/j.jtho.2016.10.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。